Clinical Trial 20372

Cancer Type: Malignant Hematology
Study Type: Other
NCT#: NCT04319237

Phase: N/A
Principal Investigator: Jim, Heather

Call 813-745-6100
or 1-800-679-0775 Learn More

Overview

Study Title

Axicabtagene Ciloleucel:Neurocognitive and Patient-Reported Outcomes

Summary

The purpose of the study is to assess self-reported side effects and neurocognitive (brain, mood and thinking) functioning among patients treated with commercial axi-cel therapy.

Objective

Aim 1: To evaluate longitudinal changes in neurocognition following axi-cel therapy Aim 2: Describe longitudinal changes in patient-reported outcomes for patients receiving axi-cel cell therapy.

Treatments

Therapies

Medications

Inclusion Criteria

Inclusion Criteria:

Diagnosed with diffuse large b-cell lymphoma, primary mediastinal b-cell lymphoma or transformed follicular lymphoma

Scheduled to receive commercial axi-cel at Moffitt Cancer Center

Able to speak and read standard english

Have no documented or observable psychiatric or neurological diagnoses that interfere with study participation (e.g., schizophrenia)

Have no history of traumatic brain injury, stroke, or dementia

Able to provide informed consent

Exclusion Criteria

If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.

Clinical Trials Search

Advanced Search